PMID- 33282739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases 
      Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard 
      Therapies.
PG  - 587692
LID - 10.3389/fonc.2020.587692 [doi]
LID - 587692
AB  - PURPOSE: Fruquintinib is an anti-vascular endothelial growth factor receptor 
      (VEGFR) agent. The FRESCO trial demonstrated that patients with metastatic 
      colorectal cancer (mCRC) refractory to standard therapies could benefit from 
      fruquintinib with tolerable adverse events (AEs). However, the efficacy and 
      safety of fruquintinib in clinical practice has scarcely been reported, 
      especially in patients with previous use of anti-VEGFR agents. METHODS: This 
      retrospective study investigated the efficacy and safety of fruquintinib in 
      patients with mCRC between January 2019 and December 2019. Progression-free 
      survival (PFS) and overall survival (OS) were assessed by a Kaplan-Meier analysis 
      and log-rank test. A Cox regression model was performed to identify independent 
      prognostic factors. RESULTS: A total of 46 patients were included. The median PFS 
      and OS were 3.1 months (95% confidence interval [CI], 1.9-4.3 months) and 9.0 
      months (95% CI, 7.2-10.8 months), respectively. Patients previously treated with 
      anti-VEGFR agents had shorter median PFS compared with those without previous use 
      of anti-VEGFR agents (1.9 vs. 3.7 months, P = 0.006), while the median OS was 
      similar between the two groups (8.5 vs. 9.0 months, P = 0.992). Multivariate 
      analysis revealed that the neutrophil-lymphocyte ratio (NLR) was an independent 
      prognostic factor in PFS (hazard ratio [HR], 2.230; 95% CI, 1.191-4.517, 
      P = 0.014) and OS (HR, 4.221; 95% CI, 1.683-10.586; P = 0.002). The most common 
      non-hematological and hematological AEs were hand-foot syndrome (37.0%) and 
      anemia (39.1%), respectively. CONCLUSION: Fruquintinib was an effective 
      third-line therapy in mCRC with tolerable AEs. Efficacy of fruquintinib was 
      decreased in patients with previous use of anti-VEGFR agents. NLR was an 
      independent prognostic factor in PFS and OS in patients treated with 
      fruquintinib.
CI  - Copyright (c) 2020 Wang, Cao, Jiang, He, You, Peng, Jin and Xia.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Cao, Huijiao
AU  - Cao H
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Jiang, Chang
AU  - Jiang C
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - He, Wenzhuo
AU  - He W
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - You, Yafei
AU  - You Y
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Peng, Kunwei
AU  - Peng K
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Jin, Yanan
AU  - Jin Y
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Xia, Liangping
AU  - Xia L
AD  - Department of VIP Region, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7691567
OTO - NOTNLM
OT  - fruquintinib
OT  - metastatic colorectal cancer
OT  - neutrophil-lymphocyte ratio
OT  - survival outcome
OT  - third-line therapy
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
PMCR- 2020/01/01
CRDT- 2020/12/07 05:35
PHST- 2020/07/27 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/12/07 05:35 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.587692 [doi]
PST - epublish
SO  - Front Oncol. 2020 Nov 13;10:587692. doi: 10.3389/fonc.2020.587692. eCollection 
      2020.